Insmed (INSM) slides 3% as investors weigh recent shelf registration and post-earnings reset

Insmed Incorporated (INSM) is down 3.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver looks like financing/dilution concerns after Insmed filed an automatic shelf registration that can be used to issue shares or other securities in the future. The stock has also been digesting a recent post-earnings/analyst price-target reset, which can add incremental pressure on down days even without fresh clinical headlines.

Details:

Insmed filed an automatic shelf registration statement on Form S-3 that registers various securities for potential issuance from time to time, a structure that can increase perceived dilution risk even if no deal is announced.

The related prospectus language indicates offerings could include common stock and debt securities, with final terms typically provided later via prospectus supplements.

After the company’s early-May quarterly update, investor attention has remained focused on the pace and profitability implications of the BRINSUPRI launch and broader spending levels.

In mid-May, at least one Wall Street firm reduced its price target while maintaining a positive rating, which can contribute to a weaker near-term tape.

Sources:

Insmed Investor Relations, U.S. Securities and Exchange Commission, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INSM Insider Trading Activity

$INSM insiders have traded $INSM stock on the open market 117 times in the past 6 months. Of those trades, 0 have been purchases and 117 have been sales.

Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 62 sales selling 180,434 shares for an estimated $26,798,950.
ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 8 sales selling 98,978 shares for an estimated $16,046,034.
MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 30 sales selling 80,543 shares for an estimated $12,097,366.
MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 10 sales selling 58,468 shares for an estimated $8,617,975.
MELVIN MD SHAROKY sold 20,000 shares for an estimated $4,100,200
SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 5 sales selling 13,662 shares for an estimated $1,886,716.
ELIZABETH M ANDERSON sold 5,000 shares for an estimated $1,022,900

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$INSM Hedge Fund Activity

We have seen 378 institutional investors add shares of $INSM stock to their portfolio, and 364 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DARWIN GLOBAL MANAGEMENT, LTD. removed 4,128,093 shares (-19.7%) from their portfolio in Q1 2026, for an estimated $675,025,767
FMR LLC added 3,232,231 shares (+32.6%) to their portfolio in Q1 2026, for an estimated $528,534,413
ORBIS ALLAN GRAY LTD removed 2,307,133 shares (-55.2%) from their portfolio in Q1 2026, for an estimated $377,262,388
ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,683,552 shares (+34.8%) to their portfolio in Q1 2026, for an estimated $275,294,423
BLACKROCK, INC. added 1,613,094 shares (+10.7%) to their portfolio in Q1 2026, for an estimated $263,773,130
CAPITAL WORLD INVESTORS added 1,362,291 shares (+inf%) to their portfolio in Q1 2026, for an estimated $222,761,824
D. E. SHAW & CO., INC. removed 1,306,469 shares (-23.1%) from their portfolio in Q4 2025, for an estimated $227,377,864

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$INSM Analyst Ratings

Wall Street analysts have issued reports on $INSM in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
UBS issued a "Buy" rating on 01/06/2026
TD Cowen issued a "Buy" rating on 12/18/2025
Goldman Sachs issued a "Buy" rating on 12/18/2025
Wells Fargo issued a "Overweight" rating on 12/16/2025
Mizuho issued a "Outperform" rating on 12/01/2025

To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.

$INSM Price Targets

Multiple analysts have issued price targets for $INSM recently. We have seen 17 analysts offer price targets for $INSM in the last 6 months, with a median target of $215.0.

Here are some recent targets:

Danielle Brill from Truist Securities set a target price of $185.0 on 05/14/2026
Benjamin Burnett from Wells Fargo set a target price of $160.0 on 05/08/2026
Vamil Divan from Guggenheim set a target price of $226.0 on 05/08/2026
Leonid Timashev from RBC Capital set a target price of $205.0 on 05/08/2026
Adam Walsh from Roth Capital set a target price of $212.0 on 04/17/2026
Eliana Merle from Barclays set a target price of $237.0 on 04/01/2026
Matthew Harrison from Morgan Stanley set a target price of $212.0 on 03/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.